Skip to main content
An official website of the United States government
Email

Precision Medicine Translational Research Networks

In 2017, five precision medicine translational research networks were launched and funded through the 21st Century Cures Act, each in a specific topic area. Additional resources for the NCI to support these initiatives permitted the Division of Cancer Treatment and Diagnosis (DCTD) to make a concerted effort to provide further funding for the research community. Successor research networks were funded in 2022 and 2023, keeping the total number of active networks at five.

Acquired Resistance to Therapy Network (ARTNet)

DCTD and NCI's Division of Cancer Biology fund ARTNet, which focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.

Cancer Immune Monitoring and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) Network

The CIMACs-CIDC Network collaborates with clinical trial investigators to design and perform biomarker and correlative studies in clinical trials of cancer immunotherapy.

Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC)

DCTD and NCI's Division of Cancer Biology fund PSRC, which focuses on the identifying, integrating, and mechanistically evaluating additional tumor microenvironment elements driving pancreatic ductal adenocarcinoma progression and response to therapy.

Patient-Derived Xenograft Development and Trial Centers Research Network (PDXNet)

PDXNet uses patient-derived models of cancer to select novel anticancer therapies for early phase clinical trials.

PRE-medical Cancer Immunotherapy Network Canine Trials (PRECINCT)

PRECINCT is performing canine immunotherapy trials in patient dogs and correlative analyses.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Precision Medicine Translational Research Networks was originally published by the National Cancer Institute.”

Email